YD Bio (YDESW) Non-Current Deferred Tax Liability (2024)
YD Bio's (YDESW) quarterly Non-Current Deferred Tax Liability came in at $1463.0 in Q4 2024.
Powered by 
Analysis
YD Bio (YDESW) Non-Current Deferred Tax Liability (2024) Analysis & Trends
YD Bio (YDESW) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $1463.0 the latest figure, recorded in Q4 2024.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $1463.0 in Q4 2024; TTM through Dec 2024 was $1463.0, a N/A change from a year earlier, with the FY2024 full-year figure at $1463.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was $1463.0 for Q4 2024 at YD Bio.
- Over five years, Non-Current Deferred Tax Liability peaked at $1463.0 in Q4 2024 and troughed at $1463.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | YD Bio | 29.02 Mn | 26.36 Mn | - |